JP2017524740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524740A5 JP2017524740A5 JP2017525320A JP2017525320A JP2017524740A5 JP 2017524740 A5 JP2017524740 A5 JP 2017524740A5 JP 2017525320 A JP2017525320 A JP 2017525320A JP 2017525320 A JP2017525320 A JP 2017525320A JP 2017524740 A5 JP2017524740 A5 JP 2017524740A5
- Authority
- JP
- Japan
- Prior art keywords
- affinity matrix
- heterodimer
- range
- polypeptide
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 24
- 239000000833 heterodimer Substances 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 239000000872 buffer Substances 0.000 claims 7
- 239000000710 homodimer Substances 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 230000003196 chaotropic effect Effects 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000012539 chromatography resin Substances 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 238000012433 multimodal chromatography Methods 0.000 claims 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims 1
- 229920000936 Agarose Polymers 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 claims 1
- 229940005991 chloric acid Drugs 0.000 claims 1
- 239000005289 controlled pore glass Substances 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000012515 MabSelect SuRe Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029463P | 2014-07-26 | 2014-07-26 | |
| US62/029,463 | 2014-07-26 | ||
| PCT/US2015/041936 WO2016018740A2 (en) | 2014-07-26 | 2015-07-24 | Purification platform for bispecific antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524740A JP2017524740A (ja) | 2017-08-31 |
| JP2017524740A5 true JP2017524740A5 (show.php) | 2020-01-30 |
| JP6702967B2 JP6702967B2 (ja) | 2020-06-03 |
Family
ID=53836215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525320A Active JP6702967B2 (ja) | 2014-07-26 | 2015-07-24 | 二重特異性抗体のための精製プラットフォーム |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10626142B2 (show.php) |
| EP (2) | EP3172221B1 (show.php) |
| JP (1) | JP6702967B2 (show.php) |
| KR (1) | KR102440737B1 (show.php) |
| CN (1) | CN107074906B (show.php) |
| AR (1) | AR101262A1 (show.php) |
| AU (1) | AU2015298156B2 (show.php) |
| DK (2) | DK3172221T3 (show.php) |
| EA (1) | EA036154B1 (show.php) |
| ES (2) | ES2881026T3 (show.php) |
| FI (1) | FI3912987T3 (show.php) |
| IL (1) | IL255198B (show.php) |
| MX (1) | MX377558B (show.php) |
| MY (1) | MY187051A (show.php) |
| PL (2) | PL3172221T3 (show.php) |
| SG (2) | SG10201900661YA (show.php) |
| TW (1) | TWI704155B (show.php) |
| WO (1) | WO2016018740A2 (show.php) |
| ZA (1) | ZA201700622B (show.php) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
| EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| KR102467302B1 (ko) | 2007-09-26 | 2022-11-14 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| FI3434767T3 (fi) | 2010-11-30 | 2026-02-12 | Chugai Seiyaku Kk | Sytotoksisuutta aiheuttava terapeuttinen aine |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3279216A4 (en) | 2015-04-01 | 2019-06-19 | Chugai Seiyaku Kabushiki Kaisha | PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER |
| EP3549606A1 (en) * | 2015-05-28 | 2019-10-09 | Bio-rad Laboratories, Inc. | Affinity ligands and methods relating thereto |
| BR112018009312A8 (pt) * | 2015-12-28 | 2019-02-26 | Chugai Pharmaceutical Co Ltd | método para promover eficiência de purificação de polipeptídeo contendo região de fc |
| MX2018012648A (es) | 2016-04-28 | 2019-01-30 | Chugai Pharmaceutical Co Ltd | Preparaciones que contienen anticuerpos. |
| JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
| EP3455243B1 (en) | 2016-05-11 | 2021-03-24 | Cytiva BioProcess R&D AB | Separation matrix |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3455241B1 (en) | 2016-05-11 | 2022-02-23 | Cytiva BioProcess R&D AB | Method of cleaning and/or sanitizing a separation matrix |
| BR112018075516A2 (pt) * | 2016-06-17 | 2019-10-01 | Genentech, Inc. | purificação de anticorpos multiespecíficos |
| KR101933656B1 (ko) | 2016-08-20 | 2018-12-28 | (주) 아이벤트러스 | 목적하는 이중특이성 항체의 선택적 생산 확인 방법 |
| WO2018038469A1 (ko) * | 2016-08-20 | 2018-03-01 | (주)아이벤트러스 | 목적하는 이중특이성 항체의 선택적 생산 확인 방법 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| MX2020003472A (es) | 2017-11-01 | 2020-08-03 | Chugai Pharmaceutical Co Ltd | Variante e isoforma de anticuerpos con actividad biologica reducida. |
| CN111902720B (zh) | 2018-03-21 | 2025-02-07 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| GB201805142D0 (en) * | 2018-03-29 | 2018-05-16 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| BR112021002724A2 (pt) * | 2018-08-17 | 2021-07-20 | Regeneron Pharmaceuticals, Inc. | método para quantificar uma quantidade de um anticorpo heterodimérico, e, sistema de cromatografia |
| US20210355215A1 (en) * | 2018-09-21 | 2021-11-18 | Teneobio, Inc. | Methods for purifying heterodimeric, multispecific antibodies |
| JPWO2020066270A1 (ja) * | 2018-09-28 | 2021-08-30 | 株式会社カネカ | κ鎖可変領域を含む抗体および／または抗体断片の製造方法 |
| CA3116717A1 (en) | 2018-10-31 | 2020-05-07 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
| MX2021005863A (es) * | 2018-11-21 | 2021-07-16 | Regeneron Pharma | Anticuerpos antiestafilococo y usos de estos. |
| WO2020112906A1 (en) * | 2018-11-26 | 2020-06-04 | North Carolina State University | Peptide ligands for capture of host cell proteiins |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| SG11202106393SA (en) | 2018-12-24 | 2021-07-29 | Sanofi Sa | Pseudofab-based multispecific binding proteins |
| EA202192810A1 (ru) | 2019-06-11 | 2022-03-05 | Регенерон Фармасьютикалз, Инк. | АНТИТЕЛА К PcrV, КОТОРЫЕ СВЯЗЫВАЮТ PcrV, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К PcrV, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| KR20220024513A (ko) * | 2019-06-13 | 2022-03-03 | 리제너론 파아마슈티컬스, 인크. | 다단 크로마토그래피 공정 동안 원치 않는 성분을 제거하기 위한 방법 |
| MY190623A (en) | 2019-12-06 | 2022-04-27 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| KR102705001B1 (ko) * | 2019-12-26 | 2024-09-10 | 에이비엘바이오 주식회사 | 단백질 a 친화성 크로마토그래피를 이용한 생리활성 펩티드의 정제 방법 |
| KR102834449B1 (ko) | 2019-12-27 | 2025-07-15 | 케이에스광학주식회사 | 투명한 방탄 적층 구조물 |
| CN115803009A (zh) | 2020-05-08 | 2023-03-14 | 瑞泽恩制药公司 | 用于治疗眼病和癌症的vegf阱和微阱及方法 |
| JP2024504388A (ja) * | 2021-01-25 | 2024-01-31 | ユーハン・コーポレイション | 抗４－１ｂｂ／抗ｈｅｒ２二重特異性抗体の精製方法 |
| GB202109246D0 (en) * | 2021-06-28 | 2021-08-11 | Cytiva Bioprocess R & D Ab | A method of separating bispecific antibodies |
| CN118414350A (zh) * | 2021-10-19 | 2024-07-30 | 阿特根公司 | 纯化具有igg fc结构域的融合蛋白的方法 |
| AU2023288640A1 (en) * | 2022-06-22 | 2024-12-12 | Cytiva Bioprocess R&D Ab | Kappa light chain-binding convection matrix |
| WO2024123698A1 (en) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
| CN116769044A (zh) * | 2023-07-11 | 2023-09-19 | 康日百奥生物科技(苏州)有限公司 | 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法 |
| WO2025073922A1 (en) * | 2023-10-04 | 2025-04-10 | Sartorius Bia Separations D.O.O. | Enhanced chromatographic separations of components in a mixture by employing chaotropic elution |
| TW202540433A (zh) | 2023-11-21 | 2025-10-16 | 美商再生元醫藥公司 | 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化 |
| WO2025131519A1 (en) * | 2023-12-21 | 2025-06-26 | Cytiva Bioprocess R&D Ab | Antibody separation with a vh3 binding separation matrix |
| WO2025173342A1 (ja) * | 2024-02-13 | 2025-08-21 | Jsr株式会社 | Ｆｃ融合タンパク質を精製するためのクロマトグラフィー用担体、及びそれを用いたＦｃ融合タンパク質の精製方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8626413D0 (en) | 1986-11-05 | 1986-12-03 | Gilliland L K | Antibodies |
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DK0826695T3 (da) | 1996-09-03 | 2002-04-15 | Gsf Forschungszentrum Umwelt | Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer |
| EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| ATE255420T1 (de) | 1998-09-25 | 2003-12-15 | Horst Lindhofer | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung |
| US20030224000A1 (en) | 2001-12-21 | 2003-12-04 | Kokai-Kun John Fitzgerald | Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| US7169903B2 (en) | 2001-12-21 | 2007-01-30 | Biosynexus Incorporated | Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria |
| ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
| EP1896504B1 (en) * | 2005-06-17 | 2012-11-21 | Wyeth LLC | Methods of purifying fc region containing antibodies |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| CL2008000883A1 (es) * | 2007-03-28 | 2008-10-03 | Wyeth6 3 | Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a |
| SG149759A1 (en) * | 2007-07-10 | 2009-02-27 | Millipore Corp | Media for affinity chromatography |
| EP2326658A4 (en) * | 2008-09-12 | 2013-04-10 | Ge Healthcare Bio Sciences Ab | REMOVAL OF REINFORCED PROTEIN AGGREGATES WITH MULTIMODAL ANION DERIVATIVES IN THE PRESENCE OF TWITTERS WITHOUT PROTEINS |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| EP2975051B1 (en) * | 2009-06-26 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| BR112012017124C1 (pt) * | 2009-12-25 | 2021-08-31 | Chugai Pharmaceutical Co Ltd | Método para produzir e para purificar um multímero polipeptídico |
| FI3434767T3 (fi) | 2010-11-30 | 2026-02-12 | Chugai Seiyaku Kk | Sytotoksisuutta aiheuttava terapeuttinen aine |
| EP2500073A1 (en) * | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
| DK2825559T3 (da) * | 2012-03-13 | 2019-06-03 | Novimmune Sa | Letisolerbare bispecifikke antistoffer med nativt immunoglobulinformat |
| US20150239991A1 (en) * | 2012-09-25 | 2015-08-27 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
-
2015
- 2015-07-21 AR ARP150102301A patent/AR101262A1/es active IP Right Grant
- 2015-07-23 TW TW104123813A patent/TWI704155B/zh active
- 2015-07-24 JP JP2017525320A patent/JP6702967B2/ja active Active
- 2015-07-24 DK DK15750182.6T patent/DK3172221T3/da active
- 2015-07-24 EP EP15750182.6A patent/EP3172221B1/en active Active
- 2015-07-24 ES ES15750182T patent/ES2881026T3/es active Active
- 2015-07-24 CN CN201580040494.9A patent/CN107074906B/zh active Active
- 2015-07-24 MY MYPI2017700080A patent/MY187051A/en unknown
- 2015-07-24 SG SG10201900661YA patent/SG10201900661YA/en unknown
- 2015-07-24 SG SG11201700157VA patent/SG11201700157VA/en unknown
- 2015-07-24 KR KR1020177003803A patent/KR102440737B1/ko active Active
- 2015-07-24 PL PL15750182T patent/PL3172221T3/pl unknown
- 2015-07-24 EA EA201790247A patent/EA036154B1/ru not_active IP Right Cessation
- 2015-07-24 MX MX2017001217A patent/MX377558B/es active IP Right Grant
- 2015-07-24 DK DK21170436.6T patent/DK3912987T3/da active
- 2015-07-24 WO PCT/US2015/041936 patent/WO2016018740A2/en not_active Ceased
- 2015-07-24 EP EP21170436.6A patent/EP3912987B9/en active Active
- 2015-07-24 AU AU2015298156A patent/AU2015298156B2/en active Active
- 2015-07-24 US US14/808,171 patent/US10626142B2/en active Active
- 2015-07-24 ES ES21170436T patent/ES2942533T3/es active Active
- 2015-07-24 FI FIEP21170436.6T patent/FI3912987T3/fi active
- 2015-07-24 PL PL21170436.6T patent/PL3912987T3/pl unknown
-
2017
- 2017-01-25 ZA ZA2017/00622A patent/ZA201700622B/en unknown
- 2017-10-22 IL IL255198A patent/IL255198B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524740A5 (show.php) | ||
| FI3912987T3 (fi) | Puhdistusalusta bispesifisille vasta-aineille | |
| JP2012515160A5 (show.php) | ||
| JP2014501758A5 (show.php) | ||
| JP2014500311A5 (show.php) | ||
| JP2016502843A5 (show.php) | ||
| JP2017086090A5 (show.php) | ||
| JP2018510867A5 (show.php) | ||
| JP2019033754A5 (show.php) | ||
| JP2018023398A5 (show.php) | ||
| JP2015512893A5 (show.php) | ||
| JP2015537212A5 (show.php) | ||
| Lu et al. | Evaluation of immunoglobulin adsorption on the hydrophobic charge-induction resins with different ligand densities and pore sizes | |
| JP2015227386A5 (show.php) | ||
| CN103382215A (zh) | 以流通方式从生物药物制剂中去除蛋白质聚集体 | |
| JP2013530156A5 (show.php) | ||
| Holstein et al. | Mobile phase modifier effects in multimodal cation exchange chromatography | |
| JP2012522736A5 (show.php) | ||
| Pezzini et al. | A comprehensive evaluation of mixed mode interactions of HEA and PPA HyperCel™ chromatographic media | |
| CN108114707B (zh) | 一种硅胶基质疏水性氨基酸键合固定相及其制备和应用 | |
| CN104226283B (zh) | 聚乙烯醇涂覆型色谱固定相及其制备方法与应用 | |
| Chmielowski et al. | Resolution of heterogeneous charged antibody aggregates via multimodal chromatography: a comparison to conventional approaches | |
| TWI660774B (zh) | 吸附材料 | |
| Wang et al. | Evaluation of mixed-mode chromatographic resins for separating IgG from serum albumin containing feedstock | |
| JP2011500757A5 (show.php) |